Show simple item record

dc.contributor.authorMontaseri, Ghazal
dc.contributor.authorBoianelli, Alessandro
dc.contributor.authorHernandez-Vargas, Esteban A
dc.contributor.authorMeyer-Hermann, Michael
dc.date.accessioned2018-10-10T08:47:31Z
dc.date.available2018-10-10T08:47:31Z
dc.date.issued2018-07-19
dc.identifier.issn1873-1732
dc.identifier.pmid30031022
dc.identifier.doi10.1016/j.pbiomolbio.2018.07.007
dc.identifier.urihttp://hdl.handle.net/10033/621511
dc.description.abstractInfluenza A virus (IAV) is a latent global threat to human health. In view of the risk of pandemics, prophylactic and curative treatments are essential. Oseltamivir is a neuraminidase inhibitor efficiently supporting recovery from influenza infections. Current common clinical practice is a constant drug dose (75 or 150 mg) administered at regular time intervals twice a day. We aim to use quantitative systems pharmacology to propose an efficient adaptive drug scheduling. We combined the mathematical model for IAV infections validated by murine data, which captures the viral dynamics and the dynamics of the immune host response, with a pharmacokinetic (PK)/pharmacodynamic (PD) model of oseltamivir. Next, we applied an adaptive impulsive feedback control method to systematically calculate the adaptive dose of oseltamivir in dependence on the viral load and the number of immune effectors at the time of drug administration. Our in silico results revealed that the treatment with adaptive control-based drug scheduling is able to either increase the drug virological efficacy or reduce the drug dose while keeping the same virological efficacy. Thus, adaptive adjustment of the drug dose would reduce not only the potential side effects but also the amount of stored oseltamivir required for the prevention of outbreaks.en_US
dc.rightsAttribution-NonCommercial-ShareAlike 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/3.0/us/*
dc.subjectImpulsive controlen_US
dc.subjectInfluenza viral infectionsen_US
dc.subjectOseltamiviren_US
dc.subjectPK/PD modelingen_US
dc.titlePK/PD-based adaptive tailoring of oseltamivir doses to treat within-host influenza viral infections.en_US
dc.typeArticleen_US
dc.contributor.departmentBRICS, Braunschweiger Zentrum für Systembiologie, Rebenring 56, 38106 Braunschweig, Germany.en_US
dc.source.journaltitleProgress in biophysics and molecular biology


Files in this item

Thumbnail
Name:
Publisher version
Thumbnail
Name:
Montaseri et al
Size:
3.141Mb
Format:
PDF
Description:
Original manuscript with Appendix ...

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-ShareAlike 3.0 United States
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 3.0 United States